Peptide reference
A synthetic GHRH analog that stimulates GH release via the GHRH receptor. The DAC-modified version binds plasma albumin, extending the half-life from minutes to days. A Phase II human trial in healthy adults showed sustained GH and IGF-1 elevation over weeks. What it does in terms of body composition or performance in non-deficient adults — that part hasn't been tested rigorously.
CJC-1295 with DAC produced sustained elevation of GH and IGF-1 in healthy adults across multiple dose levels in a Phase II trial, with a half-life of 6–8 days.
CJC-1295 is a modified 30-amino-acid analog of growth-hormone-releasing hormone that binds the GHRH receptor to trigger growth hormone release from the pituitary. It comes in two distinct forms: a long-acting version chemically bound to albumin, with a half-life of roughly six to eight days, and a short-acting version, often called MOD-GRF 1-29, with a half-life closer to thirty minutes. The two get mixed up constantly in marketing copy.
The only well-characterized human trial of CJC-1295 is a 2006 study that measured growth hormone and IGF-1 levels after dosing with the long-acting form, finding sustained elevation across days with no serious adverse effects reported. That trial measured hormone levels, not muscle, fat, or any functional outcome. Twenty years later, there's still no published Phase 2 or Phase 3 trial of CJC-1295 for any indication.
CJC-1295 has no FDA-approved drug application and isn't on either of the FDA's 2026 or 2027 PCAC review waves. That's not because it was overlooked: PCAC already reviewed CJC-1295 in December 2024 and voted against adding it to the Section 503A compounding list, citing insufficient human safety data and a lack of reproducible efficacy evidence.
Yes. CJC-1295 falls under WADA's S2 category for growth-hormone- releasing factors, prohibited at all times for athletes subject to testing, whether in or out of competition. That classification applies regardless of how the FDA's compounding review has gone.
Wolverine Health is building physician-supervised peptide protocols. Get early access.
Join the waitlist